RhumbLine Advisers
TARA icon

RhumbLine Advisers’s Protara Therapeutics TARA Stock Holding History

RhumbLine Advisers’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Buy
63,245
+31,170
+97% +$148K ﹤0.01% 3188
2026
Q1 		$167K Buy
32,075
+5,210
+19% +$30.8K ﹤0.01% 3205
2025
Q4 		$143K Sell
26,865
-7,272
-21% -$40.4K ﹤0.01% 3328
2025
Q3 		$148K Buy
34,137
+2,596
+8% +$8.4K ﹤0.01% 3369
2025
Q2 		$95.6K Buy
+31,541
New +$109K ﹤0.01% 3542

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

RhumbLine Advisers's TARA Position: Q2 2026 in Review

RhumbLine Advisers increased its Protara Therapeutics (TARA) stake by 97% in Q2 2026, buying an estimated $148K and bringing the position to 63,245 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #3188.

RhumbLine Advisers first reported a position in TARA in Q2 2025 and has held it in 5 quarters since. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • RhumbLine Advisers held 63,245 shares of Protara Therapeutics worth $242K as of Q2 2026.
  • RhumbLine Advisers bought 31,170 Protara Therapeutics shares in Q2 2026, an estimated $148K.
  • Protara Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3188 holding.
  • RhumbLine Advisers first reported a position in Protara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.